NASDAQ · Biotechnology

LRMR (LRMR) Stock

$3.98 +4.19% NASDAQ: LRMR Healthcare

Valuation

MetricValue
Price$3.98
Market Cap$413.45M
P/E Ratio-1.47
P/B Ratio3.65
P/S Ratio0.00
EPS (TTM)$-2.27
52-Week High$6.42
52-Week Low$2.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-212.82%
ROA-113.70%
ROCE-220.51%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio2.18

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-50.0M$-37.0M$-42.0M$-91.0M$-172.0M
Net Profit$-51.0M$-35.0M$-37.0M$-81.0M$-166.0M
EPS$-2.93$-1.33$-0.84$-1.32$-2.27
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$79.0M$126.0M$96.0M$200.0M$146.0M
Total Liabilities$14.0M$16.0M$14.0M$28.0M$68.0M
Cash$70.0M$27.0M$27.0M$33.0M$85.0M
Borrowings$6.0M$5.0M$6.0M$5.0M$4.0M

Latest News

Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy Insider Monkey · Jul 15, 2026 LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000 Stocktwits · Jul 8, 2026 Here’s What Citi Thinks About Larimar Therapeutics (LRMR) Insider Monkey · Jul 3, 2026 LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns Stocktwits · Jul 2, 2026 Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR) InvestorsHub · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-42.0M$-28.0M$-33.0M$-71.0M$-113.0M
Investing Cash Flow$24.0M$-91.0M$33.0M$-86.0M$100.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$2.0M$-43.0M$0$6.0M$52.0M
Free Cash Flow$-42.0M$-28.0M$-34.0M$-71.0M$-113.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-45.00%
Quick Ratio4.29
Interest Coverage—
Return 1Y6.65%
Return 3Y28.12%
Return 5Y-64.27%

Ownership

Insiders Held1.15%
Institutions Held86.19%
Institutions Float Held87.19%
Institutional HolderSharesReport Date
Deerfield Management Company, L.P35,606,9742026-03-31
Blue Owl Capital Holdings LP7,120,0072026-03-31
Blackrock Inc.3,752,2002026-03-31
Millennium Management Llc3,625,2782026-03-31
AIGH Capital Management LLC3,000,0002026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
AMRNAmarin Corporation plc $14.58 +0.80% -9.00 $301.45M 0.00%
ANNX $5.37 +0.75% -3.71 $879.83M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%

About LRMR

LRMR is led by CEO Carole S. Ben-Maimon, employs 65 people, headquartered in US, publicly traded since 2014.

LRMR stock trades at $3.98 with a market capitalization of $413.45M. The stock is valued at a price-to-earnings (P/E) ratio of -1.47, price-to-book of 3.65, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.22 and $6.42, and currently trades 38.0% below its 52-week high.

On profitability, LRMR generates a return on equity (ROE) of -212.82%, return on capital employed of -220.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides